Prelude Therapeutics Inc Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2019 to Q3 2024

Taxonomy & unit: us-gaap: USD
Description: Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary: Prelude Therapeutics Inc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2019 to Q3 2024.
Prelude Therapeutics Inc Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $5.93M, a 11.8% decline year-over-year.
Prelude Therapeutics Inc Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $23.5M, a 8.09% decline year-over-year.
Prelude Therapeutics Inc annual Share-based Payment Arrangement, Expense for 2023 was $25.6M, a 1.88% increase from 2022.
Prelude Therapeutics Inc annual Share-based Payment Arrangement, Expense for 2022 was $25.1M, a 20.1% increase from 2021.
Prelude Therapeutics Inc annual Share-based Payment Arrangement, Expense for 2021 was $20.9M, a 275% increase from 2020.

Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)

Share-based Payment Arrangement, Expense, Quarterly (USD)

Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q3 2024	$23.5M	$5.93M	-$789K	-11.8%	Jul 1, 2024	Sep 30, 2024	10-Q	2024-11-06
Q2 2024	$24.3M	$6.1M	-$635K	-9.43%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-12
Q1 2024	$24.9M	$5.55M	-$709K	-11.3%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-07
Q4 2023	$25.6M	$5.91M	+$67K	+1.15%	Oct 1, 2023	Dec 31, 2023	10-K	2024-02-15
Q3 2023	$25.5M	$6.72M	+$273K	+4.24%	Jul 1, 2023	Sep 30, 2023	10-Q	2024-11-06
Q2 2023	$25.3M	$6.73M	+$705K	+11.7%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-12
Q1 2023	$24.6M	$6.26M	-$573K	-8.39%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-07
Q4 2022	$25.1M	$5.85M	+$70K	+1.21%	Oct 1, 2022	Dec 31, 2022	10-K	2024-02-15
Q3 2022	$25.1M	$6.44M	-$591K	-8.4%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-01
Q2 2022	$25.7M	$6.03M	+$1.79M	+42.3%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-03
Q1 2022	$23.9M	$6.83M	+$2.94M	+75.7%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-08
Q4 2021	$20.9M	$5.78M	+$2.65M	+85%	Oct 1, 2021	Dec 31, 2021	10-K	2023-03-15
Q3 2021	$18.3M	$7.03M	+$5.56M	+378%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-14
Q2 2021	$12.7M	$4.24M	+$3.61M	+576%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-09
Q1 2021	$9.11M	$3.89M	+$3.52M	+973%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-10
Q4 2020	$5.58M	$3.12M			Oct 1, 2020	Dec 31, 2020	10-K	2022-03-17
Q3 2020		$1.47M	+$1.18M	+396%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-12
Q2 2020		$627K			Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-12
Q1 2020		$362K			Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-11
Q3 2019		$297K			Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-10

* An asterisk sign (*) next to the value indicates that the value is likely invalid.